{
    "clinical_study": {
        "@rank": "18454", 
        "arm_group": [
            {
                "arm_group_label": "NovoSeven\u00ae", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Eptacog alfa A 6 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the bioequivalence\n      of eptacog alfa A 6 mg and NovoSeven\u00ae in healthy male subjects."
        }, 
        "brief_title": "Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven\u00ae in Healthy Male Subjects", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Haemophilia A", 
            "Haemophilia A With Inhibitors", 
            "Haemophilia B", 
            "Haemophilia B With Inhibitors", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemophilia B", 
                "Hemophilia A", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, age 18-55 years, both inclusive, at the time of signing informed consent\n\n          -  Body Mass Index (BMI) 18.5-30 kg/m^2, both inclusive\n\n          -  Good general health based on assessment of medical history, vital signs, physical\n             examination, ECG (electrocardiogram), and laboratory data at screening, as judged by\n             the investigator\n\n        Exclusion Criteria:\n\n          -  Known history of thromboembolic event(s) or potential thromboembolic risk as judged\n             by the investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084810", 
            "org_study_id": "NN7777-4087", 
            "secondary_id": [
                "2013-003163-63", 
                "U1111-1145-6620"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "NovoSeven\u00ae", 
                "description": "All subjects will receive one i.v. (intravenous, into the vein) injection of 90\u03bcg/kg.\nEach subject will be allocated to two treatment periods separated by a wash-out period of a week.", 
                "intervention_name": "activated recombinant human factor VII", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eptacog alfa A 6 mg", 
                "description": "All subjects will receive one i.v. injection of 90\u03bcg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.", 
                "intervention_name": "eptacog alfa (activated)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 24, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven\u00ae", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the curve", 
                "safety_issue": "No", 
                "time_frame": "After a single i.v. injection based on FVIIa activity assessments up to 36 hours post dose"
            }, 
            {
                "measure": "Maximum concentration", 
                "safety_issue": "No", 
                "time_frame": "After a single i.v. injection based on FVIIa activity assessments up to 36 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084810"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency of adverse events (including serious adverse events)", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to 7 weeks following first trial product administration"
            }, 
            {
                "measure": "Incidence of antibodies", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to 7 weeks following first trial product administration"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}